Systemic Lupus Erythematosus

Sep 27, 2024

6 Upcoming Bispecific Antibodies Beyond Oncology

Apr 04, 2023

HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

Jan 27, 2023

Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation

Feb 15, 2022

Pfizer & Lilly’s JAK Inhibitors Drug; FDA Approves Lilly’s Bebtelovimab; GSK’s Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian

Sep 08, 2021

Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?

Jun 10, 2021

Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M

Feb 02, 2021

Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Jan 26, 2021

Aurinia’s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End

Apr 13, 2020

Is Hydroxychloroquine the answer to all the COVID-19 questions?

Dec 18, 2017

Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies

Newsletter/Whitepaper